India’s Drug controller general of India(DCGI) gives permission to Bharat Biotech for Phase -3 clinical trials after completion of Phase -1 and Phase 2 trials of COVAXIN. The phase-3 clinical trials will be done in 25 centre in 26,000 participants across India.
Hypertension, or high blood pressure, has become a silent but deadly crisis in India. The…
Elon Musk's Neuralink has made groundbreaking strides in its mission to integrate brain-computer interface (BCI)…
Air pollution, a silent but pervasive environmental hazard, is increasingly impacting human health worldwide. Long-term…
Fake Medicine: Did you know that fake medicines can cause serious damage to your body's…
Surgical Site Infection: In India, the rate of infections after surgery is rapidly increasing. Surgical…
A recent study conducted by the Indian Council of Medical Research (ICMR) reveals concerning insights…